In this issue

**Research Article**

**Parkon® in the treatment of multiple sclerosis. A pilot study**

Published On: August 07, 2020 | Pages: 001 - 005

Author(s): Goldstein NI, Golubev VL and Goldstein RN*

Multiple Sclerosis (MS) is one of the most common chronic demyelinating diseases of the central nervous system. The disease affects and relatively quickly leads to disability in mainly people 15-40 years of age. The development of MS can occur progressively or with exacerbations and remissions. The pathogenesis of the disease is based on an autoimmune process directed ...

**Mini Review**

**Cardiac Effects of Parkinson’s Disease**

Published On: December 19, 2020 | Pages: 006 - 007

Author(s): Hüsnü Deirmenci*, Eftal Murat Bakirci and Hikmet Hamur

Parkinson’s disease, which has symptoms and signs such as tremor, bradykinesia, rigidity and postural instability, is the most common neurodegenerative disease after Alzheimer’s disease. In Parkinson’s disease, pathological mechanisms such as abnormal accumulation of protein aggregates, disruption of protein clearance pathways, oxidative stress, neuroinflammation, mit ...

Abstract View | Full Article View | DOI: 10.17352/ojpdt.000008

Abstract View | Full Article View | DOI: 10.17352/ojpdt.000009